BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marcolino VA, Pimentel TC, Barão CE. What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. Eur J Pharmacol 2020;887:173467. [PMID: 32777212 DOI: 10.1016/j.ejphar.2020.173467] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Segrelles-Calvo G, de S Araújo GR, Frases S. Systemic mycoses: a potential alert for complications in COVID-19 patients. Future Microbiol 2020;15:1405-13. [PMID: 33085538 DOI: 10.2217/fmb-2020-0156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Kelleni MT. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. SN Compr Clin Med 2021;:1-5. [PMID: 33644693 DOI: 10.1007/s42399-021-00824-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
3 Elmokadem AH, Bayoumi D, Mansour M, Ghonim M, Saad EA, Khedr D. COVID-19-associated acute invasive fungal sinusitis: Clinical and imaging findings. J Neuroimaging 2022. [PMID: 35043509 DOI: 10.1111/jon.12967] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zaheer T, Pal K, Abbas RZ, Torres MDPR. COVID-19 and Ivermectin: Potential threats associated with human use. J Mol Struct 2021;1243:130808. [PMID: 34149064 DOI: 10.1016/j.molstruc.2021.130808] [Reference Citation Analysis]
5 Banerjee I, Robinson J, Asim M, Sathian B, Banerjee I. Mucormycosis and COVID-19 an epidemic in a pandemic? Nepal J Epidemiol 2021;11:1034-9. [PMID: 34290893 DOI: 10.3126/nje.v11i2.37342] [Reference Citation Analysis]
6 Booz GW, Zouein FA. Science unites a troubled world: Lessons from the pandemic. Eur J Pharmacol 2021;890:173696. [PMID: 33130278 DOI: 10.1016/j.ejphar.2020.173696] [Reference Citation Analysis]
7 Parlak C, Alver Ö, Ouma CNM, Rhyman L, Ramasami P. Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights. Drug Res (Stuttg) 2021. [PMID: 34535038 DOI: 10.1055/a-1585-1323] [Reference Citation Analysis]
8 Aljarba NH, Hasnain MS, Bin-Meferij MM, Alkahtani S. An in-silico investigation of potential natural polyphenols for the targeting of COVID main protease inhibitor. J King Saud Univ Sci 2022;34:102214. [PMID: 35811756 DOI: 10.1016/j.jksus.2022.102214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Khan S, Attar F, Bloukh SH, Sharifi M, Nabi F, Bai Q, Khan RH, Falahati M. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase. Int J Biol Macromol 2021;181:605-11. [PMID: 33766591 DOI: 10.1016/j.ijbiomac.2021.03.112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]